ID Care President, Dr. Ronald Nahass, interviewed
by local TV station regarding COVID-19 Drug Trial

May 28, 2020
Blog

NEW BRUNSWICK, N.J. — In the federal government’s latest move to treat the nation’s most critical COVID-19 patients, the drug Remdesivir will be supplied to six states, including New Jersey.

The drug is the first to show success in speeding up the recovery process.

“We noticed that the temperatures come down more quickly in patients who are getting this medicine and they’re less likely to need a ventilator,” said Dr. Ronald Nahass, a clinical professor at Rutgers Robert Wood Johnson Medical School.

Dr. Nahass is leading a series of clinical trials at Rutgers. Through the 90 patients enrolled, they’ve seen positive results since remdesivir has a direct effect on the lifecycle of the virus.

“It’s a very well-tolerated medicine which is also great the side effect profile is very favorable so that always makes us feel good,” said Dr. Nahass.

View the full interview here.